Table 1 FDA approved PD1 checkpoint inhibitors
From: PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report
Drug Name | Target | Year FDA Approved | Solid Organ rejections |
|---|---|---|---|
Nivolumab | PD-1 | 2014 | 2 cases (NSCLC, Melanoma) |
Pembrolizumab | PD-1 | 2014 | 2 cases (SCC, Melanoma) |
Atezolizumab | PD-L1 | 2016 | None to date |
Avelumab | PD-L1 | 2017 | None to date |
Durvalumab | PD-L1 | 2017 | None to date |